The Claim
Annual multimodal screening using CA125 blood testing followed by transvaginal ultrasound in average-risk postmenopausal women aged 50–74 increases the proportion of ovarian and tubal cancers diagnosed at early stage (I/II) by 39.2% compared to no screening, but does not reduce ovarian cancer mortality over 16 years of follow-up.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Getting yearly blood tests and ultrasounds for women over 50 might catch more ovarian cancers early, but it doesn’t help them live longer, even after 16 years.
See the scientific wording
Annual multimodal screening using CA125 blood testing followed by transvaginal ultrasound for average-risk postmenopausal women aged 50–74 increases the proportion of ovarian and tubal cancers diagnosed at early stage (I/II) by 39.2% compared to no screening, but does not reduce ovarian cancer mortality over 16 years of follow-up.
What the research says
1 studyThis big study checked if yearly blood tests and ultrasounds could catch ovarian cancer earlier in older women — and it did! But even though more cancers were found early, it didn’t help more women live longer. So the claim is right on both counts.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.